Literature DB >> 8314488

Community acquired viral hepatitis B and C in the United States.

M J Alter1.   

Abstract

In the United States, most reported cases of hepatitis B occur in adults as a result of behavioural, lifestyle, or occupational exposures, but a significant number of children also become infected in well defined settings. Although only 1-3% of acute hepatitis B virus (HBV) infections occur in children under 5 years of age, they account for 20-30% of all chronic infections. A new strategy for HBV prevention in the USA includes integration of HBV vaccine into childhood immunisation schedules. Vaccination strategies that target high risk groups have not been effective. To determine the frequency and severity of community acquired chronic hepatitis C, patients with acute non-A, non-B hepatitis identified in four sentinel counties in the United States were followed prospectively. Hepatitis C virus (HCV) infection was found in 106 (82%) of 130 patients. Ninety three per cent of the HCV positive patients had a risk factor for their infection: 59% parenteral, 6% sexual or household, and 28% low socioeconomic level. Chronic hepatitis developed in 62%, independently of the risk factor for infection. HCV-RNA persisted in most patients, including those with biochemical resolution of their hepatitis. This study suggests that HCV may be a major cause of liver disease and persistent viraemia in the United States.

Entities:  

Mesh:

Year:  1993        PMID: 8314488      PMCID: PMC1373998          DOI: 10.1136/gut.34.2_suppl.s17

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions.

Authors:  L Mimms; D Vallari; L Ducharme; P Holland; I K Kuramoto; J Zeldis
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

2.  Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.

Authors:  M J Alter; P J Coleman; W J Alexander; E Kramer; J K Miller; E Mandel; S C Hadler; H S Margolis
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

3.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.

Authors:  M J Alter; S C Hadler; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; L A Moyer; H A Fields; D W Bradley
Journal:  JAMA       Date:  1990-11-07       Impact factor: 56.272

4.  Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays.

Authors:  R D Aach; C E Stevens; F B Hollinger; J W Mosley; D A Peterson; P E Taylor; R G Johnson; L H Barbosa; G J Nemo
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

5.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

6.  Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees.

Authors:  M J Beach; E L Meeks; L T Mimms; D Vallari; L DuCharme; J Spelbring; S Taskar; J B Schleicher; K Krawczynski; D W Bradley
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

7.  Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification.

Authors:  K Krawczynski; M J Beach; D W Bradley; G Kuo; A M di Bisceglie; M Houghton; G R Reyes; J P Kim; Q L Choo; M J Alter
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

8.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies.

Authors:  M J Alter; S C Hadler; H S Margolis; W J Alexander; P Y Hu; F N Judson; A Mares; J K Miller; L A Moyer
Journal:  JAMA       Date:  1990-03-02       Impact factor: 56.272

9.  Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population.

Authors:  M J Alter; R J Gerety; L A Smallwood; R E Sampliner; E Tabor; F Deinhardt; G Frösner; G M Matanoski
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226

Review 10.  Hepatitis B: evolving epidemiology and implications for control.

Authors:  H S Margolis; M J Alter; S C Hadler
Journal:  Semin Liver Dis       Date:  1991-05       Impact factor: 6.115

  10 in total
  5 in total

1.  Hepatitis C virus infection in cocaine users--a silent epidemic.

Authors:  H H Harsch; J Pankiewicz; A S Bloom; C Rainey; J K Cho; L Sperry; E A Stein
Journal:  Community Ment Health J       Date:  2000-06

2.  Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area.

Authors:  M J Dwyer; P G McIntyre
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

3.  Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia.

Authors:  D Palmović; J Crnjaković-Palmović
Journal:  Eur J Epidemiol       Date:  1994-10       Impact factor: 8.082

4.  Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.

Authors:  Sahar El Hadad; Hesa Al-Hamdan; Sabah Linjawi
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

5.  Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.

Authors:  Nicole Brenner; Alexander J Mentzer; Julia Butt; Kathrin L Braband; Angelika Michel; Katie Jeffery; Paul Klenerman; Barbara Gärtner; Paul Schnitzler; Adrian Hill; Graham Taylor; Maria A Demontis; Edward Guy; Stephen J Hadfield; Rachael Almond; Naomi Allen; Michael Pawlita; Tim Waterboer
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.